U.S. Health Care REITs Stock News

CNX Resources (CNX) has drawn investor attention after a recent pullback, with the stock down about 8% over the past month and roughly 19% over the past 3 months. See our latest analysis for CNX Resources. That recent pullback sits within a mixed picture, with the share price down about 9% year to date and roughly 19% over 3 months, while the 1 year total shareholder return is 3.6% and the 3 and 5 year total shareholder returns are very strong. This suggests long term holders have still seen...

Earlier this week, Refeyn and Bio-Techne announced a first-of-its-kind integrated workflow that links Bio-Techne’s MauriceFlex™ icIEF fractionation system with Refeyn’s TwoMP mass photometry platform, enabling four-hour, single-molecule characterization of charge and size variants in bispecific antibodies and biosimilars using nanogram-level samples. This pairing allows researchers to directly connect charge heterogeneity with molecular weight and aggregation in a single streamlined...

On June 1, 2026, O'Reilly Automotive increased its share repurchase authorization by an additional US$2.00 billion to a total of US$31.75 billion and extended the buyback program by three years. This enlarged, longer-duration buyback underscores management’s confidence in the company’s strong cash generation and high-return capital allocation, reinforcing its focus on shareholder returns. Next, we’ll examine how this expanded, longer-term buyback authorization might reshape O'Reilly...

Pinnacle West Capital recently completed a US$499.58 million fixed‑income offering of 4.650% senior unsecured notes due June 1, 2029, following the closure of a US$40.75 million dividend reinvestment common stock shelf and ahead of a special call held on June 8, 2026. Together, the sizable debt issuance, prior equity program completion, and subsequent special call highlight an active period of balance sheet planning that may shape how investors interpret the company’s capital plans and...

In recent months, Arbor Realty Trust has faced weaker net interest income growth, rising loan distress in its roughly US$12.00 billion portfolio, and a dividend cut following a soft first-quarter 2026 earnings report. Together with declining earnings per share, tangible book value per share, and earnings estimates, these developments highlight mounting profitability and credit pressures tied to tougher commercial real estate conditions. Next, we’ll examine how the elevated distress in...

C3.ai, Inc. reported past fourth-quarter revenue of US$51.6 million and a full-year total of US$250.27 million to 30 April 2026, alongside wider net losses and loss per share compared with the previous year. At the same time, C3.ai is extending its multi-year collaboration with Shell to deepen AI-driven reliability and root-cause analysis across Shell’s global operations, underscoring a contrast between customer adoption progress and internal execution challenges. We’ll now examine how...

Recent interest in City Holding (CHCO) has centered on its reputation as a consistent dividend payer, offering a yield that exceeds both its banking peers and the broader S&P 500 index. See our latest analysis for City Holding. Recent dividend affirmations and the CFO title change have come alongside steady share price momentum, with a 30 day share price return of 6.64% and a 1 year total shareholder return of 11.87%. Longer term total shareholder returns over 3 and 5 years remain...

Earlier this week, Lazard reported preliminary May 2026 assets under management of about US$284.8 billion, with US$11.6 billion of market appreciation offset by US$1.4 billion in client withdrawals and US$0.7 billion of currency depreciation. At the same time, recent insider share sales without any reported insider buying have raised fresh questions about how management views near-term business conditions. We’ll now examine how Lazard’s recent net outflows and currency headwinds may...

Li Auto Inc. reported past May 2026 deliveries of 33,350 vehicles, taking cumulative deliveries to about 1.70 billion units by May 31, alongside first-quarter 2026 revenue of CNY 22,982.91 million and a net loss of CNY 2,289.53 million. Alongside weaker recent deliveries and guidance flagging year-over-year declines in second-quarter volumes and revenue, Li Auto is updating its product lineup and bylaws while preparing for a European launch and a June technology showcase. We’ll now examine...

In early June 2026, Amneal Pharmaceuticals reported positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s disease and also received FDA approval, with 180 days of Competitive Generic Therapy exclusivity, for its romidepsin injection solution for cutaneous T-cell lymphoma. The CREXONT data highlighted meaningful gains in “Good On” time and motor control across prior treatment groups, while the romidepsin approval brought an oncology medicine back to the U.S. market in a...

Establishment Labs Holdings (ESTA) has drawn fresh attention after recent share price moves, with the stock up about 11% over the past month and roughly 25% in the past 3 months. See our latest analysis for Establishment Labs Holdings. The recent 7 day share price return of 9.74% and 90 day share price return of 24.95% come on top of a 1 year total shareholder return of 106.18%, pointing to momentum that has been building rather than fading. If you are comparing ESTA with other faster growing...

Recently, Zacks upgraded Brink's to a Rank #2 (Buy), citing a positive shift in analyst earnings estimates and a stronger earnings outlook for the company. This ratings change highlights how revisions to profit expectations can shape investor perception of Brink's evolving cash-management and digital services business model. Next, we'll examine how this more optimistic earnings outlook might influence Brink's broader investment narrative built around AMS and digital solutions. The future of...

Earlier this week, Vornado Realty Trust reported that PENN 2 in New York’s PENN DISTRICT is now 90% leased after signing 10–12 year full-floor agreements with technology tenants Veeva and Altana AI, which is establishing its new headquarters there. This leasing progress at a flagship redevelopment, coupled with increased interest across office REITs, highlights how high-quality, amenity-rich assets may be attracting tenants even as the broader office sector adjusts to new working...

On June 8, 2026, PTC Therapeutics announced that board member Alethia Young resigned to focus on other work commitments, while simultaneously entering a consulting agreement that keeps her advising the company through June 8, 2027. This move comes as PTC Therapeutics reports record revenue driven by strong global uptake of SEPHIENCE, underscoring the company’s emphasis on continuity of commercial and advisory expertise. We’ll now examine how record SEPHIENCE-driven revenue, alongside Alethia...

In May 2026, Maximus, Inc. entered into a second amendment to its Amended and Restated Credit Agreement, securing an additional US$325,000,000 in Tranche B-1 term loans with terms matching its existing term B facilities. The new borrowing, earmarked for revolver repayment, share repurchases, working capital, and related fees, highlights Maximus’ active use of leverage to fund capital returns while maintaining liquidity. We’ll now examine how Maximus’ expanded term loan capacity and planned...

CG Oncology (CGON) is back in focus as investors look ahead to key data from its Phase 3 PIVOT-006 trial and a planned regulatory filing for bladder cancer therapy cretostimogene later this year. See our latest analysis for CG Oncology. Recent excitement around cretostimogene and upcoming conference appearances has not prevented some volatility, with the share price down 20.77% over the past month and 12.78% over 90 days, yet still posting a 31.42% year to date share price return and a very...

Rising tensions between the US and Iran, self defense strikes, and related crude supply disruptions have pushed oil prices higher, putting Diamondback Energy (FANG) firmly back on investors’ radar as a key US shale producer. See our latest analysis for Diamondback Energy. Short term, the stock has been choppy, with the share price falling 6.67% over the past week even as it gained 11.04% over 90 days and delivered a 35.39% total shareholder return over the past year. This pattern suggests...

Tarsus Pharmaceuticals recently presented at the 46th Annual William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York, highlighting its eye-care portfolio and commercial progress. These conferences gave the company a high-visibility forum to emphasize growing real-world adoption of XDEMVY, supported by intensive direct-to-consumer marketing efforts. We’ll now examine how accelerating XDEMVY awareness and uptake, spotlighted at these...

In recent days, Clear Street analyst Tim Moore highlighted Willdan Group’s potential upside, citing expected revenue and adjusted EBITDA growth from power grid modernization and rising demand for energy-efficient and AI datacenter solutions, while company insiders sold about US$6.1 million of stock over the past three months. This combination of bullish analyst commentary on AI datacenter exposure and concurrent insider selling offers a contrasting signal about management’s and the market’s...

On 3 June 2026, Bristol Myers Squibb announced a clinical trial collaboration and supply agreement under which Arcus Biosciences will provide its investigational HIF-2a inhibitor casdatifan for new combination arms in the Phase 1/2 ROSETTA RCC-208 study in advanced renal cell carcinoma, while both parties retain rights to their respective assets in this non-exclusive deal. This collaboration highlights growing external interest in casdatifan as a potential component of combination regimens,...

Popular (BPOP) is back in focus after recent analyst commentary highlighted upward revisions to earnings estimates and a strong momentum style score. This has drawn attention to how these signals may influence sentiment around its stock. See our latest analysis for Popular. Recent price action has been supportive for that improving sentiment, with a 90 day share price return of 19.32% and a 1 year total shareholder return of 51.92%. Multi year total shareholder returns above 100% point to...

Nabors Industries recently faced increased investor attention after geopolitical tensions and sector-wide energy volatility raised concerns about operational risks, particularly in the Gulf region. At the same time, some analysts view Nabors as trading at a substantial discount to their fair value estimates, despite ongoing margin and capital intensity headwinds. We’ll now examine how rising geopolitical risk in key operating regions could influence Nabors Industries’ existing investment...

Over the last 7 days, the United States market has experienced a 4.1% drop, yet it remains up by 21% over the past year with anticipated earnings growth of 18% per annum in the coming years. In this fluctuating environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

Over the last 7 days, the United States market has experienced a 4.1% drop, yet it remains up by 21% over the past year with earnings forecasted to grow by 18% annually. In this context of fluctuating market conditions, companies with high insider ownership and strong revenue growth potential can offer intriguing opportunities for investors seeking stability and alignment of interests between management and shareholders.